质子泵抑制剂对PCI术后氯吡格雷抗血小板作用的影响

被引：4

作者：

陈斗仁

机构：

[1] 淮安市第二人民医院

来源：

山东医药 | 2013年 / 53卷 / 10期

关键词：

氯吡格雷; 质子泵抑制剂; 泮托拉唑; 血小板聚集;

D O I：

暂无

中图分类号：

R541.4 [冠状动脉（粥样）硬化性心脏病（冠心病）];

学科分类号：

1002 ; 100201 ;

摘要：

目的探讨经皮冠状动脉介入术(PCI)后抗血小板治疗中应用质子泵抑制剂(PPI)对氯吡格雷抗血小板作用的影响。方法选择PCI术后患者336例,术后立即服用氯吡格雷600 mg及阿司匹林500 mg,随后应用氯吡格雷75 mg/d、阿司匹林100 mg/d。术后同时服用PPI类药物以预防消化道出血的患者148例(观察组),其中122例给予口服泮托拉唑,14例给予口服奥美拉唑,12例给予口服埃索美拉唑。没有服用PPI类药物的188例患者作为对照组。在服用氯吡格雷48 h后检测两组血小板聚集率,以氯吡格雷抵抗(CLR)评价抗血小板聚集效果。比较不同PPI药物与CLR的相关性。结果两组血小板阻抗变化差异无统计学意义(P均>0.05)。两组CLR发生率差异无统计学意义(P>0.05)。奥美拉唑、埃索美拉唑对CLR影响较大。结论接受氯吡格雷+阿斯匹林双重抗血小板治疗的患者服用PPI标准剂量时,短期内不影响氯吡格雷的抗血小板作用。

引用

页码：66 / 68

页数：3

共 13 条

[1] Variable platelet response to aspirin and clopidogrel in atherothrombotic disease [J].

Maree, Andrew O. ;

Fitzgerald, Desmond J. .

CIRCULATION, 2007, 115 (16) :2196-2207

[2] HPLC-MS法测定氯吡格雷酸人体尿药浓度及氯吡格雷酸经尿排泄研究 [J].

刘园园 ;

唐立超 ;

沙克亚 ;

丁黎 ;

文爱东 ;

杨林 .

药学进展, 2010, 34 (10) :463-467

[3]

Clopidogrel with orwithout Omeprazole in Coronary Artery Disease. Bhatt DL,Cryer BL,Contant CFet al. The New England Journal of Medicine . 2010

[4]

Cytochrome P450 2C19 681G_A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. D Trenk,W Hochholzer,MF Fromm,LE Chialda,A Pahl,CM Valina,C Stratz,P chmiebusch,HP Bestehorn,HJ Büttner,FJ Neumann. Journal of the American College of Cardiology . 2008

[5]

Cytochrome P 450 polymorphisms and response to clopidogrel. Mega JL,Close SL,Wiviott SD. The New England Journal of Medicine . 2009

[6]

The effect of CYP2C19polymorphism on thepharmacokinetis and pharmacodynamics of clopidogrel:a possible mechanism forclopidogrel resistance. Kim KA,Park PW,Hong SJ,et al. Clinical Pharmacology and Therapeutics . 2008

[7]

Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Lau W C,Gurbel P A,Watkins P B,et al. Circulation . 2004

[8]

Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Gurbel PA,Bliden KP,Hiatt BL,et al. Circulation . 2003

[9]

Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention. Results of the ARMYDA-PRO (Antiplatelet Therapy for Reduction of MYocardial Damage During Angioplasty-Platelet Rea. G Patti,A Nusca,F Mangiacapra. Journal of the American College of Cardiology . 2008

[10]

Variable Platelet Response to Aspirin and Clopidogrel in Atherothrombotic Disease. Maree AO,Fitzgerald DJ. Circulation . 2007

← 1 2 →